VitalHub UK Limited acquires Induction Healthcare Group PLC (2025)

Deal facts

Buyer: VitalHub UK Limited
Target: Induction Healthcare Group PLC
Deal value: Not disclosed
Announced: 16 June 2025
Status: Completed
Sector: Healthcare
Country: United Kingdom
Consideration: cash

Sources

What we know

VitalHub UK Limited has agreed to acquire Induction Healthcare Group PLC in a strategic acquisition within the healthcare sector. The transaction involves a cash consideration structure and was announced on 16 June 2025. The target company operates from the United Kingdom, and the deal is classified as a strategic acquisition rather than a management buyout or merger of equals. No specific deal value was disclosed in the available reporting, and the currency for any potential consideration remains unreported.

The transaction has reached a completed status as of the latest available information. This development marks the conclusion of the acquisition process between the two entities. The deal represents a significant consolidation within the UK healthcare landscape, bringing the target under the ownership of the acquiring firm. Regulatory approvals and other standard conditions were satisfied to allow the completion to proceed. The transaction is now finalised with no further pending steps required for closure.

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

2 updates

18 Jun 2025Scheme effectiveClosed
VitalHub UK Limited to acquire Induction Healthcare Group PLC
{ "headline": "Scheme Effective", "issuer": "Induction Healthcare Group (INHC)", "announcement_date": "2025-06-18T07:00:00", "category_code": "Other M&A", "body": "FOR IMMEDIATE RELEASE \n\n THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION \n\n \n\n 18 June 2025 \n\n RECOMMENDED CASH ACQUISITION OF \n\n INDUCTION HEALTHCARE GROUP PLC (\"Induction\") \n\n by \n\n VITALHUB UK LIMITED (\"Bid
LSE RNS
16 Jun 2025Court sanction
VitalHub UK Limited to acquire Induction Healthcare Group PLC
{ "headline": "Court Sanction of Scheme of Arrangement", "issuer": "Induction Healthcare Group (INHC)", "announcement_date": "2025-06-16T12:46:00", "category_code": "Scheme of Arrangement", "body": "FOR IMMEDIATE RELEASE \n\n \n\n 16 June 2025 \n\n RECOMMENDED CASH ACQUISITION OF \n\n INDUCTION HEALTHCARE GROUP PLC (\"Induction\") \n\n by \n\n VITALHUB UK LIMITED (\"Bidco\") \n\n (a di
LSE RNS

OpinionExit Mode editorial

We see the completed acquisition of Induction Healthcare Group PLC by VitalHub UK Limited as a clear signal of consolidation within the UK healthcare technology sector. Announced on 16 June 2025, this strategic move brings together two distinct entities under a single ownership structure. The deal is structured as a straightforward cash transaction, which removes the immediate complexity of share-swap valuations and aligns the interests of the seller with immediate liquidity. For the SME founder reading this, the simplicity of the consideration type often reflects a buyer who has conducted thorough due diligence and is confident in the target's standalone value proposition without needing to tie a portion of the price to future performance metrics.

The strategic nature of this acquisition suggests that VitalHub UK Limited views Induction Healthcare Group PLC as a critical piece of its broader service offering rather than a mere financial asset. In the healthcare sector, regulatory scrutiny is always a factor, yet the speed of completion implies that any necessary competition reviews or regulatory clearances were either pre-emptively addressed or fell below the thresholds requiring extensive CMA intervention. This is a vital lesson for founders operating in highly regulated fields. You must assume that any change of control will trigger a review of your existing contracts and compliance frameworks. The buyer will need to ensure that your current regulatory standing does not become a liability post-closing.

We believe this deal highlights the growing appetite for pure cash exits in the mid-market, where buyers are willing to pay a premium for certainty and speed. The absence of an earn-out structure in the public announcement indicates that the seller's management team likely secured a clean break, a rare and valuable outcome in a market often dominated by deferred payment conditions. This approach reduces the risk of post-deal disputes over performance targets and allows the founder to walk away with a definitive sum. It underscores that a well-prepared business with robust governance can command a premium for its immediate integration potential.

Your immediate action this week should be to conduct a full review of your customer contracts to identify any change-of-control covenants that could be triggered by a sale. Many founders overlook these clauses until the term sheet is signed, only to find that key clients have the right to terminate or renegotiate terms upon acquisition. Map out every agreement that requires third-party consent for a transfer of ownership and prepare a briefing note for your board on how to manage these notifications before you even start talking to buyers.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More strategic acquisition deals More from VitalHub UK Limited All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history